Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
- 31 October 2007
- journal article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 82 (10), 1179-1184
- https://doi.org/10.4065/82.10.1179
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Thalidomide–dexamethasone as primary therapy for advanced multiple myelomaAmerican Journal of Hematology, 2005
- Multiple MyelomaThe New England Journal of Medicine, 2004
- Multiple myelomaThe Lancet, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaThe New England Journal of Medicine, 2003
- Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed MyelomaJournal of Clinical Oncology, 2002
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 1996
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990